检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in primary refractory patients (pts) and in pediatric pts with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) in the phase 2 CheckMate 744 study

C. Mauz-Koerholz, T. Leblanc, P. Harker-Murray,M. Mascarin, G. Michel,S. Cooper,A. Beishuizen, K. J. Leger,A. Garaventa,S. Buffardi, L. Brugieres, K. M. Kelly, P. D. Cole, R. A. Drachtman, T. Manley,S. Francis,M. Sacchi,S. Daw

ONCOLOGY RESEARCH AND TREATMENT（2019）

引用 0|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要